Treatment of Follicular Lymphoma with Localized Contiguous Non-Bulky Disease (Lugano Stage I or II)
This page covers follicular lymphoma presenting as localized, contiguous, non-bulky disease — Lugano stage I or II — a distinct subset in which curative-intent local treatment is the cornerstone of management.
In patients with localized FL (contiguous, non-bulky stage I or II), local radiotherapy with curative potential is recommended (1A).
Patients with bulky disease or other risk factors should be managed as advanced disease.
Treatment Approach — Partial Overview
For this presentation, involved-site radiation therapy is the primary treatment of choice. Depending on the patient's specific circumstances and anatomical considerations, alternative or complementary approaches may also be appropriate. The complete evidence-based regimen — including all options, selection criteria, and sequencing — is available via the link below.
References
DOI: 10.3390/cancers18030395
- In patients with localized FL (contiguous, non-bulky stage I or II), local radiotherapy with curative potential is recommended (1A).
- Patients with bulky disease or other risk factors should be managed as advanced disease.
- ISRT at a dose of 24 Gy is the treatment of choice (1A), demonstrating curative potential.
- Lower radiotherapy doses (4 Gy) offer less durable efficacy but may be beneficial in specific anatomical locations (e.g., lacrimal gland, parotid glands) to minimize adverse effects (2B).
- Conversely, the combination of radiotherapy with rituximab (one weekly dose for 4 weeks) provides a favorable balance between efficacy and toxicity (2B).
- For patients who are not candidates for radiotherapy due to conditions predisposing to adverse effects (e.g., dry syndrome, hypothyroidism), rituximab monotherapy (1 weekly dose of 375 mg/m2 for 4 weeks) may be considered.
- In selected stage I FL patients, radical surgery may represent a potential exclusive treatment option.
View source ↗